project-idea
MOC Drug Compass: A Patient-Facing Drug Evidence Explorer for Mucinous Ovarian Carcinoma The first comprehensive drug efficacy dataset for mucinous ovarian carcinoma was just generated using patient-derived tumor organoids — for a cancer subtype that has almost no clinical evidence base and is routinely treated with regimens designed for a different
project-idea
TLS-Scope: An Open-Source Spatial Transcriptomics Pipeline for Tertiary Lymphoid Structure Classification A hierarchical graph neural network operating on spatial transcriptomics data can classify tertiary lymphoid structures as immunogenic or tolerogenic — a distinction with direct implications for predicting immunotherapy response that bulk RNA analysis cannot make. The AI model described in
project-idea
ImmunoComboDB: A Curated Database of CD4+ T Cell-Boosting + Checkpoint Inhibitor Combination Studies An orally available small molecule (Alphataxin) that boosts tumor-infiltrating CD4+ T cells combined with anti-PD-1 achieved 37.5% objective response rate in colon cancer mice — significantly better than either monotherapy alone. Checkpoint immunotherapy response is frequently limited not
project-idea
MuxDx Planner: A Multiplex Antibody Panel Designer for Lung Cancer Diagnosis A single multiplexed antibody panel can now deliver comprehensive lung cancer diagnosis — tumor classification, biomarker assessment, and clinical features — from one tissue section, avoiding the tissue exhaustion that plagues sequential IHC testing. Designing a multiplexed antibody panel for cancer
project-idea
SCLC SubtypeTracker: Longitudinal Liquid Biopsy Subtype Monitor for Tarlatamab Patients SCLC transcription factor subtype (ASCL1, NEUROD1, POU2F3) can be inferred from circulating chromatin in blood, and treatment with tarlatamab can drive subtype switching as a resistance mechanism — making serial liquid biopsy monitoring clinically actionable. This research opens the door to
project-idea
StromalAtlas PDAC: An Interactive Single-Cell Fibroblast Subtype Browser for Pancreatic Cancer A single-cell RNA-seq study of 42 PDAC tumors identified an NFATC2-expressing CAF subpopulation associated with better survival — demonstrating that CAF heterogeneity in pancreatic cancer carries prognostic information that bulk analysis misses. The cancer-associated fibroblast field is exploding with single-cell
project-idea
SrcMatch: A Biomarker-to-Inhibitor Pairing Tool for Src-Driven Cancers Six different Src inhibitors showed highly heterogeneous efficacy across OSCC cell lines, with sensitivity correlated to which oncogenic signaling pathways were active — suggesting that pathway activation profile, not just Src expression, should drive drug selection. The fundamental insight from this study is
project-idea
MetastaMap: Open Protocol + Data Repository for Ex Vivo Organ Invasion Studies Breast cancer cells preferentially invaded lung and liver ECM scaffolds but not intestinal scaffolds in the new ex vivo assay — perfectly matching clinical metastatic tropism patterns. The ex vivo invasion platform described in this paper fills a critical gap
breast-cancer
Metabolic enzyme SIRT5 drives chemotherapy resistance in triple-negative breast cancer by rewiring energy pathways Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes, partly because a significant fraction of patients don't respond to chemotherapy even at first treatment. This study used proteomics and metabolomics on
brain-cancer
Key regulatory axis keeps brain cancer stem cells alive and fuels drug resistance in childhood brain tumors Sonic Hedgehog medulloblastoma (SHH-MB) is a brain tumor that can relapse after treatment, driven by stem/progenitor-like cells that resist chemotherapy. Understanding what maintains these cells is critical to preventing relapse. This study
breast-cancer
RUNX1 loss combined with p53 deletion creates aggressive ER+ breast tumors with immune cell infiltration RUNX1 is a transcription factor that is mutated in a subset of estrogen receptor-positive (ER+) breast cancers, but whether RUNX1 loss actually causes tumors to form has been unclear. Using genetically engineered mice with mammary-specific
ovarian-cancer
First comprehensive drug testing platform for rare mucinous ovarian cancer reveals new treatment options Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer subtype that behaves very differently from common high-grade serous ovarian cancer — and is treated poorly with the standard ovarian cancer regimens designed for the latter. A major
